Osteoarthritis of the knee Musculoskeletal Diseases Osteoarthritis
Conditions
Interventions
Patients were randomised to receive one of four treatments:
1. Lower Molecular Weight HA (LMW)
2. Higher Molecular Weight HA (HMW)
3. Combined lower and higher molecular weight and different concentr
Sponsors
Lawson Health Research Institute (Canada)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Radiographic evidence of grade 1 to 3 medial compartment Osteoarthritis (OA) 2. Did not exhibit non-arthritis related disease 3. Gave consent as approved by the University of Western Ontario Ethics Review Board 4. Age range at recruitment was 45 - 85 years, both men and women
Exclusion criteria
Exclusion criteria: 1. Previous injection with HA or corticosteroids 2. Bilateral knee OA 3. Unstable cardiovascular or metabolic disease 4. Unable to commit to follow-up period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in self-paced 40-m walking pain using the Visual Analogue Scale (VAS), measured at V1 - V7. Timepoints: V1 = Baseline V2 = Week 1 V3 = Week 2 V4 = Week 3 V5 = Week 4 V6 = Week 12 V7 = Week 16 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Improvement in seated rest pain Visual Analogue Scale (VAS), measured at V1 - V7 2. Patient global satisfaction using a 5-point numerical scale, with 1 representing not satisfied and 5 completely satisfied, measured at V1 - V7 3. Presence of adverse events and concomitant medications, measured at V1 - V7 Timepoints: V1 = Baseline V2 = Week 1 V3 = Week 2 V4 = Week 3 V5 = Week 4 V6 = Week 12 V7 = Week 16 | — |
Countries
Canada
Outcome results
None listed